BioStock: Clinical effects observed with Alligator’s 4-1BB agonist
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Nyhetsbrev: Fem ”skitprodukter” att se upp med / Veckans aktie: Vändning i sikte med 30 procents uppsida

Pressmeddelande

BioStock: Clinical effects observed with Alligator’s 4-1BB agonist

Cision Publicerad: 14 Mar 2024 10:41
Alligator Bioscience

Through its partnership with the US-based biotech Aptevo Therapeutics, Alligator Bioscience is evaluating the bispecific antibody ALG.APV-527 for the treatment of solid tumours in a phase I dose-escalation trial. The companies have announced positive interim results from the dose escalation part of the study, and BioStock spoke with Alligator’s CEO Søren Bregenholt to learn more.

Read the article at biostock.se:

Clinical effects observed with Alligator’s 4-1BB agonist - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Alligator Bioscience

Läses av andra just nu

Om aktien Alligator Bioscience

Senaste nytt